Applied Therapeutics, Inc. (APLT)

USD 1.08

(-1.82%)

Market Cap (In USD)

125.66 Million

Revenue (In USD)

9.99 Million

Net Income (In USD)

-119.76 Million

Avg. Volume

2.46 Million

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.95-10.624
PE
-
EPS
-
Beta Value
2.018
ISIN
US03828A1016
CUSIP
03828A101
CIK
1697532
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Shoshana Shendelman Ph.D.
Employee Count
-
Website
https://www.appliedtherapeutics.com
Ipo Date
2019-05-14
Details
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy. Its preclinical stage products include AT-003 for the treatment diabetic retinopathy; AT-104, a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukemia. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.